by dyadic | Jan 20, 2022 | Press Releases
JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving,...
by dyadic | Dec 22, 2021 | Press Releases
JUPITER, Fla., Dec. 22, 2021 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving,...
by dyadic | Dec 17, 2021 | Press Releases
JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving,...
by dyadic | Nov 10, 2021 | Press Releases
•COVID-19 vaccine candidate, DYAI-100, continues to advance towards first-in-human clinical trial to validate C1 produced proteins are safe in humans and further accelerate global C1 platform adoption •Five non-COVID-19 infectious disease monoclonal...
by dyadic | Nov 9, 2021 | Press Releases
JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving,...
by dyadic | Oct 27, 2021 | Press Releases
JUPITER, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving,...
